{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:48:35Z","timestamp":1792050515868,"version":"4.4.0"},"reference-count":26,"publisher":"Informa UK Limited","issue":"28","license":[{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.2217\/fon-2022-0656","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T09:51:46Z","timestamp":1660211506000},"page":"3133-3141","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":36,"title":["LIBRETTO-432, a Phase III Study of Adjuvant Selpercatinib or Placebo in Stage IB-IIIA\n            <i>RET<\/i>\n            Fusion-Positive Non-Small-Cell Lung Cancer"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3031-5807","authenticated-orcid":false,"given":"Masahiro","family":"Tsuboi","sequence":"first","affiliation":[{"name":"National Cancer Center Hospital East,\rKashiwa,\rJapan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W","family":"Goldman","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine,University of California Los Angeles,\rLos Angeles,\rCA 90095,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-0258","authenticated-orcid":false,"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[{"name":"Guangdong Lung Cancer Institute,Guangdong Provincial People\u2019s Hospital &amp; Guangdong Academy of Medical Sciences,\rGuangzhou,\rChina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L","family":"Johnson","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute,\rNashville,\rTN 37203,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology,Hospital Universitario 12 de Octubre,H120-CNIO Lung Cancer Unit,Universidad Complutense &amp; Ciberonc,\rMadrid,\rSpain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Chih-Hsin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology,National Taiwan University Hospital &amp; Graduate Institute of Oncology,National Taiwan University,\rTaipei,\rTaiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[{"name":"Gustave Roussy,Villejuif France &amp; Paris Saclay University,\rFrance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiji","family":"Su","sequence":"additional","affiliation":[{"name":"Eli Lilly &amp; Company,\rIndianapolis,\rIN 46225,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo H","family":"Chao","sequence":"additional","affiliation":[{"name":"Eli Lilly &amp; Company,\rNew York,\rNY 10016,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Drilon","sequence":"additional","affiliation":[{"name":"Department of Medicine,Memorial Sloan-Kettering Cancer Center &amp; Weill Cornell Medical College,\rNew York,\rNY 10065,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,8,11]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31937"},{"key":"e_1_3_5_4_1","unstructured":"ESMO Guidelines Committee . PanchardD PopatS KerrKet al.Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis treatment and follow-up (2022). www.esmo.org\/content\/download\/347819\/6934778\/1\/ESMO-CPG-mNSCLC-15SEPT2020.pdf"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181c5920c"},{"key":"e_1_3_5_6_1","unstructured":"NCCN . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Non-small cell lung cancer (2022). www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.04.011"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.4401"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.08.009"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02748"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000483"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2015.09.009"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02098-5"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170"},{"key":"e_1_3_5_15_1","first-page":"3","article-title":"Immunophenotype and response to immunotherapy of RET-rearranged lung cancers","author":"Offin M","year":"2019","unstructured":"Offin M , GuoR, WuSLet al. Immunophenotype and response to immunotherapy of RET-rearranged lung cancers. JCO Precis. Oncol.3 (2019).","journal-title":"JCO Precis. Oncol."},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/LCTT.S192830"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.10.014"},{"key":"e_1_3_5_18_1","first-page":"S0169","article-title":"Perioperative targeted therapy for oncogene-driven NSCLC","volume":"22","author":"Liu SY","year":"2022","unstructured":"Liu SY , ZhangJT, ZengKH, WuYL. Perioperative targeted therapy for oncogene-driven NSCLC. Lung Cancer.22, S0169\u2013S5002 (2022).","journal-title":"Lung Cancer."},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.175"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12275"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2015.09.016"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.1477"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy137"},{"key":"e_1_3_5_24_1","volume-title":"AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","author":"Brandhuber BB","year":"2016","unstructured":"Brandhuber BB , HaasJ, TuchBet al. The development of LOXO-292, a potent, KDR\/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Munich, German (2016). (POSTER 441)"},{"key":"e_1_3_5_25_1","volume-title":"Abstract Book of the European Lung Cancer Congress (ELCC)","author":"Drilon A","year":"2022","unstructured":"Drilon A , SubbiahV, GautschiOet al. Durability of efficacy and safety with selpercatinib inpatients (pts) with RET fusion+ non-small cell lung cancer(NSCLC). In: Abstract Book of the European Lung Cancer Congress (ELCC). ELCC (2022)."},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005653"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0935"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027071"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-0656","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:43:46Z","timestamp":1719125026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-0656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":26,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.2217\/fon-2022-0656"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-0656","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-06-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}